tiprankstipranks
Advertisement
Advertisement

DMAC Stock Latest News

DiaMedica Therapeutics Highlights Clinical Gains Amid Trial Risks
Company AnnouncementsDiaMedica Therapeutics Highlights Clinical Gains Amid Trial Risks
5d ago
DMAC
DiaMedica Therapeutics Furnishes 2025 Financial Results and Business Update
PremiumCompany Announcements
DiaMedica Therapeutics Furnishes 2025 Financial Results and Business Update
10d ago
DMAC
DiaMedica Therapeutics reports FY25 EPS (70c), consensus (68c)
PremiumThe Fly
DiaMedica Therapeutics reports FY25 EPS (70c), consensus (68c)
10d ago
DMAC
DMAC Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
DMAC Upcoming Earnings Report: What to Expect?
13d ago
DMAC
DiaMedica Therapeutics receives Health Canada clearance to initiate DM199 study
PremiumThe Fly
DiaMedica Therapeutics receives Health Canada clearance to initiate DM199 study
1M ago
DMAC
Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
PremiumThe FlyOmega takes new stake in Rocket Companies, exits ArriVent Biopharma
2M ago
ET
ABR
DiaMedica Therapeutics Raises Capital via Share Offering
Premium
Company Announcements
DiaMedica Therapeutics Raises Capital via Share Offering
3M ago
8K
DMAC
DiaMedica Therapeutics named a Top Idea for 2026 at Lake Street
Premium
The Fly
DiaMedica Therapeutics named a Top Idea for 2026 at Lake Street
3M ago
DMAC
DiaMedica Therapeutics provides DM199 update following FDA meeting
PremiumThe Fly
DiaMedica Therapeutics provides DM199 update following FDA meeting
4M ago
DMAC
DiaMedica Advances DM199 Preeclampsia Program After FDA Pre-IND Meeting
PremiumCompany Announcements
DiaMedica Advances DM199 Preeclampsia Program After FDA Pre-IND Meeting
4M ago
DMAC
Buy Rating Affirmed for Diamedica Therapeutics Amid Promising DM199 Trial Progress
PremiumRatings
Buy Rating Affirmed for Diamedica Therapeutics Amid Promising DM199 Trial Progress
5M ago
DMAC
Microsoft initiated, Home Depot downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Microsoft initiated, Home Depot downgraded: Wall Street’s top analyst calls
5M ago
HD
MP
DiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe FlyDiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald
5M ago
DMAC
DiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
DiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald
5M ago
DMAC
DiaMedica Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
DiaMedica Therapeutics Reports Q3 2025 Financial Results
5M ago
DMAC
DiaMedica Therapeutics’ Earnings Call: Mixed Outlook
PremiumCompany Announcements
DiaMedica Therapeutics’ Earnings Call: Mixed Outlook
5M ago
DMAC
DiaMedica Therapeutics Reports Q3 2025 Financial Results and Clinical Progress
PremiumCompany Announcements
DiaMedica Therapeutics Reports Q3 2025 Financial Results and Clinical Progress
5M ago
DMAC
DiaMedica Therapeutics reports Q3 EPS (17c), consensus (16c)
PremiumThe Fly
DiaMedica Therapeutics reports Q3 EPS (17c), consensus (16c)
5M ago
DMAC
DMAC Earnings this Week: How Will it Perform?
PremiumPre-Earnings
DMAC Earnings this Week: How Will it Perform?
5M ago
DMAC
DiaMedica Therapeutics initiated with a Buy at TD Cowen
PremiumThe FlyDiaMedica Therapeutics initiated with a Buy at TD Cowen
5M ago
DMAC
Buy Rating for Diamedica Therapeutics: Promising Potential of DM199 in Preeclampsia Treatment
Premium
Ratings
Buy Rating for Diamedica Therapeutics: Promising Potential of DM199 in Preeclampsia Treatment
5M ago
DMAC
ReMEDy2 Trial: A Potential Game-Changer for Acute Ischemic Stroke Treatment
Premium
Company Announcements
ReMEDy2 Trial: A Potential Game-Changer for Acute Ischemic Stroke Treatment
5M ago
DMAC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >